A Review of Literature on Breast Cancer: Molecular Insights, Clinical Approaches, and Future Perspectives

Year : 2025 | Volume : 03 | Issue : 02 | Page : 15 20
    By

    Ritu,

  • Anshika Rosha,

  1. Assistant Professor, Department of Nursing, Galgotias School of Nursing, Galgotias University, Uttar Pradesh, India
  2. Nursing Tutor, Department of Nursing, Galgotias School of Nursing, Galgotias University, Uttar Pradesh, India

Abstract

Breast cancer is the leading cause of morbidity and mortality in women globally. Although both men and women can get the condition, women are more likely to get it, and its prevalence has been rising globally in recent years. The epidemiology, risk factors, pathophysiology, diagnosis, treatment options, and survival rates of breast cancer are all examined in this review of recent research. Breast cancer can show up as a lump in the breast, changes in the breast’s size or form, skin dimpling, or nipple discharge, among other signs. Screening methods that can identify issues early and enhance prognosis include magnetic resonance imaging (MRI), mammography, and ultrasonography. Breast tumors can be precisely classified using histopathological investigation and molecular profiling, which informs therapy choices. The study examines the molecular subtypes of breast cancer, the genetic and environmental factors that influence risk, and developments in early detection, including the function of screening programs. With a focus on the value of personalized medicine, treatment approaches such as surgery, chemotherapy, radiation, targeted therapy, and immunotherapy are examined. There are still issues, especially with aggressive subtypes like triple-negative breast cancer, despite advancements in research and treatment. Immunotherapy and molecular profiling are two potential future research avenues that could enhance survival rates and results.

Keywords: Mammography, ultrasonography, estrogen receptor, menstruation, triple-negative breast cancer

[This article belongs to International Journal of Oncological Nursing and Practices ]

How to cite this article:
Ritu, Anshika Rosha. A Review of Literature on Breast Cancer: Molecular Insights, Clinical Approaches, and Future Perspectives. International Journal of Oncological Nursing and Practices. 2025; 03(02):15-20.
How to cite this URL:
Ritu, Anshika Rosha. A Review of Literature on Breast Cancer: Molecular Insights, Clinical Approaches, and Future Perspectives. International Journal of Oncological Nursing and Practices. 2025; 03(02):15-20. Available from: https://journals.stmjournals.com/ijonnp/article=2025/view=235472


References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May; 71(3): 209–249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
  2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7; 266(5182): 66–71. doi: 10.1126/science.7545954. PMID: 7545954.
  3. Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022 Oct; 42(10): 913–936. doi: 10.1002/cac2.12358. Epub 2022 Sep 8. PMID: 36074908; PMCID: PMC9558690.
  4. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022 Feb 27; 2(1): 1–9. doi: 10.1016/j.jncc.2022.02.002. PMID: 39035212; PMCID: PMC11256658.
  5. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Héry C, Heanue M. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010 Aug 11; 341: c3620. doi: 10.1136/bmj.c3620. Erratum in: BMJ. 2010;341:c4480. LaVecchia, Carlo [corrected to La Vecchia, Carlo]. PMID: 20702548; PMCID: PMC2920378.
  6. Cirak Y, Furuncuoglu Y, Yapicier O, Alici S, Argon A. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer. Int J Clin Exp Pathol. 2015 May 1; 8(5): 5345–53. PMID: 26191236; PMCID: PMC4503107.
  7. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003 Aug; 39(12): 1718–29. doi: 10.1016/s0959-8049(03)00118–7. PMID: 12888367.
  8. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer. 2006 Nov 15; 119(10): 2417–22. doi: 10.1002/ijc.22160. PMID: 16964611.
  9. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Should we use incidence, survival or mortality to assess breast cancer trends in European women? Nat Clin Pract Oncol. 2006 May; 3(5): 228–9. doi: 10.1038/ncponc0489. PMID: 16682983.
  10. Frischbier HJ. Die Screening-Mammographie und ihre Bedeutung für die Senkung der Brustkrebsmortalität [Screening mammography and its significance for decreasing breast cancer mortality]. Z Arztl Fortbild (Jena). 1991 Oct 25; 85(20): 995–9. German. PMID: 1776292.
Regular Issue Subscription Review Article
Volume 03
Issue 02
Received 12/10/2025
Accepted 05/11/2025
Published 12/11/2025
Publication Time 31 Days
80

Login


My IP

PlumX Metrics